Btcp Pharma Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BTCP PHARMA, and when can generic versions of BTCP PHARMA drugs launch?
BTCP PHARMA has two approved drugs.
There are fifteen US patents protecting BTCP PHARMA drugs.
There are seventy-seven patent family members on BTCP PHARMA drugs in thirty-one countries and thirteen supplementary protection certificates in five countries.
Summary for Btcp Pharma
| International Patents: | 77 |
| US Patents: | 15 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
Drugs and US Patents for Btcp Pharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Btcp Pharma | SUBSYS | fentanyl | SPRAY;SUBLINGUAL | 202788-001 | Jan 4, 2012 | DISCN | Yes | No | 8,835,460 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Btcp Pharma | SUBSYS | fentanyl | SPRAY;SUBLINGUAL | 202788-007 | Aug 30, 2012 | DISCN | Yes | No | 8,835,460 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Btcp Pharma | SUBSYS | fentanyl | SPRAY;SUBLINGUAL | 202788-006 | Aug 30, 2012 | DISCN | Yes | No | 9,241,935 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Btcp Pharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Btcp Pharma | LAZANDA | fentanyl citrate | SPRAY, METERED;NASAL | 022569-001 | Jun 30, 2011 | 9,814,705 | ⤷ Subscribe |
| Btcp Pharma | LAZANDA | fentanyl citrate | SPRAY, METERED;NASAL | 022569-001 | Jun 30, 2011 | 6,432,440 | ⤷ Subscribe |
| Btcp Pharma | LAZANDA | fentanyl citrate | SPRAY, METERED;NASAL | 022569-002 | Jun 30, 2011 | 9,078,814 | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for BTCP PHARMA drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Sublingual Spray | 0.4 mg/spray | ➤ Subscribe | 2017-05-22 |
International Patents for Btcp Pharma Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Portugal | 2670674 | ⤷ Subscribe |
| European Patent Office | 2641595 | ⤷ Subscribe |
| Hong Kong | 1192522 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Btcp Pharma Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1769785 | C300522 | Netherlands | ⤷ Subscribe | PRODUCT NAME: FENTANYL EN DOSERINGSAPPLICATOR; REG. NO/DATE: EU/2/11/127/001 20111006 |
| 1635783 | 132014902242643 | Italy | ⤷ Subscribe | PRODUCT NAME: FENTANIL IN QUALSIASI FORMA PROTETTA DAL BREVETTO DI BASE(PECFENT); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/10/644/001-004, 20100831 |
| 1769785 | C300521 | Netherlands | ⤷ Subscribe | PRODUCT NAME: FENTANYL; REG NO/DATE: EU/2/11/127/001 20111006 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
